Sorry, you need to enable JavaScript to visit this website.

ATIVAN (lorazépam) Bibliographie

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.
Pfizer reconnaît les préoccupations du grand public concernant la situation liée à la COVID-19, qui continue d'évoluer. Cliquez ici pour savoir comment nous avons réagi.


  1. Alps BJ, Harry TVA, Southgate PJ. The pharmacology of lorazepam, a broad-spectrum tranquillizer. Curr Med Res Opin 1975;1:239-261.
  2. Ban TA. ECEDEU Reports. Psychopharmacol Bull 1973;9:69-71.
  3. Brunaud M, Rocand J. Une nouvelle benzodiazépine, le lorazépam, mise au point pharmacologique. Agressologie 1972;13:363-375.
  4. Caille G, Lacasse Y, Vezina M, Porter R, Shaar S, Darke A. A novel route for benzodiazepine administration: a sublingual formulation of lorazepam. In: Manzo, L., et al., eds. Advances in neurotoxicology. Pergamon Press, 1980.
  5. Calixto N, De Costa Maia JA. Influence of lorazepam on ocular pressure in patients with glaucoma. Curr Ther Res 1975;17:156-160.
  6. Coates H. Lorazepam and diazepam in severe neurotic illness. Curr Med Res Opin 1972; 1:74-7.
  7. Conner JT, Parson N, Katz RL, Wapner S, Bellville JW. Evaluation of lorazepam and pentobarbital as surgical premedicants. Clin Pharmacol Ther 1976;19:24-29.
  8. De Buck R. Clinical experience with lorazepam in the treatment of neurotic patients. Curr Med Res Opin 1973;1:291-295.
  9. Denaut M, Yernault JC, De Coster A. Double blind comparison of the respiratory effects of parental lorazepam and diazepam in patients with chronic obstructive lung disease. Curr Med Res Opin 1975;2:611-615.
  10. Dundee JW, George KA. Relative amnesic actions of diazepam, flunitrazepam and lorazepam in man. Br J Clin Pharmacol 1977;4:45-50.
  11. Dundee JW, Johnston HML, Gray RC. Lorazepam as a sedative-amnesic in an intensive care unit. Curr Med Res Opin 1976;4:290-295.
  12. Eaves D, Jain VK, Swinson RP. A double blind controlled trial of lorazepam and diazepam in the treatment of anxiety. Curr Med Res and Opinion 1973;1:265-268.
  13. Elliot HW. Metabolism of lorazepam. Br J Anaesth 1976;48:1017-1023.
  14. Gale G, Galloon S. Lorazepam as a premedication. Can Anaesth Soc J 1976;23:22-28.
  15. Galloon S, Gale GD, Lancee WJ. Comparison of lorazepam and diazepam as Premedicants. Br J Anaesth 1977;49:1256-1269.
  16. Gasser CJ, Kaufman RD, Bellville WJ. Respiratory effects of lorazepam, pentobarbital and pentazocine. Clin Pharmacol Ther 1975;18:170-174.
  17. Gluckman MI. Pharmacology of 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepan-2-one (lorazepan;WY-4036). Arzneimittelforsch 1971;21:1049-1055.
  18. Goldberg HL, Finnerty RJ, Cole JO. A study of anti-anxiety effects of WY-4036. Compr Psychiatry 1974;15:95-200.
  19. Greenblatt DJ, et al. Clinical pharmacokinetics of lorazepam. Clin Pharmacol Ther 1976; 20:329-339.
  20. Haider I. Evaluation of a new tranquillizer – WY-4036 in the treatment of anxiety. Br J Psychiatry 1971;119:597-598.
  21. Haider I. A comparative trial of lorazepam and diazepam. Brit J Psychiatry 1971;119:599-600.
  22. Hedges A, Turner P, Harry TVA. Preliminary studies on central effects of lorazepam a new benzodiazepine. J Clin Pharmacol 1971;2:423-427.
  23. Heisterkamp DV, Cohen PJ. The effect of intravenous premedication with lorazepam (Ativan), pentobarbitone or diazepam on recall. Br J Anaesth 1975;47:79-81.
  24. Knapp RB, Fierro L. Evaluation of the cardiopulmonary safety and effects of lorazepam as a premedicant. Anesth Analg 1974;53:122-124.
  25. Knowles JA, Comer WH, Reulius HW. Disposition of 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one (lorazepam) in humans. Arzneimittelforsch 1971;21:1055-1059.
  26. Nanivadekar AS, Wig NN, Khorana AB, Master RS, Kulkarni SS. A multicenter investigation of lorazepam in anxiety neurosis. Curr Ther Res 1973;15:432-439.
  27. Owen G, Hatfield GK, Pollock JJ, Steinberg AJ, Tucker WE, Agersborg HPK (Jr). Toxicity studies of lorazepam, a new benzodiazepine, in animals. Arzneimittelforsch 1971;21:1065-1073.
  28. Rickels K, Case WG, Csanalosi I, Pereira-Ogan JA, Parish L, Bell PJ. Lorazepam in anxiety: a controlled study. J Int Med Res 1974;2:20-25.
  29. Saxena BM, Singh AN, Nelson HL, Mahutte G: Clinical experience with oral and parenteral lorazapam. Curr Ther Res 1979;25:1-15.
  30. Schillings RT, Shader SR, Ruelius HW. Urinary Metabolites of 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one (lorazepam) in humans and four animal species. Arzneimittelforsch 1971;21:1059-1065.
  31. Singh AN, Saxena B. A Comparison of lorazepam, diazepam and placebo in the treatment of anxiety states. Curr Ther Res 1974;16:149-162.
  32. Stein L, Berger BD. Psychopharmacology of 7-chloro-5-(o-chlorophenyl)-1, 3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one (lorazepam) in squirrel, monkey and rat. Arzneimittelforsch 1971;21:1072-1078.


Numéro de contrôle : 221513
31 janvier 2019


Il n'y a aucune nouveauté actuellement

Communiquer avec l'Information pharmaceutique de Pfizer

Signalez un effet indésirable
1 866 723-7111